ASTH vs PRVA: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PRVA is the larger of the two ($3.24B market cap): the incumbent the market prices for continued execution (23.25x forward earnings, beta 0.75). ASTH is the smaller challenger ($1.47B), cheaper on forward earnings (8.49x): more room to run, but more to prove. If you believe PRVA earns its premium (23.25x forward earnings, so the market expects more from it), PRVA fits. If you believe in paying less for profit, ASTH fits at 8.49x.
ASTH vs PRVA: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ASTH | PRVA | What it tells you |
|---|---|---|---|
| Market cap | $1.47B | $3.24B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.49 | 23.25 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 27.39 | 97.38 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.24 | 0.75 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 34% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.70 | 3.97 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ASTH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ASTH and PRVA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASTH and PRVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASTH and PRVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Astrana Health (ASTH) do?
Astrana Health trades on Nasdaq under ASTH and was known as Apollo Medical Holdings (AMEH) until the 2024 rebrand. The company organizes independent physicians into risk-bearing networks and then contracts with health plans on a capitated basis, meaning it accepts a fixed per-member payment and keeps the difference if it can manage care for less. The business reports in three segments: Care Partners, the risk-bearing network arm that produces the large majority of revenue; Care Delivery, the owned and affiliated clinics; and Care Enablement, the technology and management-services platform that the networks run on. The membership base skews heavily toward Medicare Advantage, with Medicaid, commercial and ACO REACH or Medicare Shared Savings lives filling out the rest, and the geographic footprint is still concentrated in California even after expansion into Nevada, Texas and other states.
What does Privia Health Group (PRVA) do?
Privia Health Group is a national physician-enablement company headquartered in Arlington, Virginia, and its structure is unusual enough that it drives everything about the financials. Physicians keep owning their own Affiliated Practices and the buildings, staff and equipment inside them, and they join a single large Privia Medical Group in their market as owners of it. Privia holds the payer contracts, negotiates reimbursement, maintains the patient records and supplies the Privia Platform (technology plus revenue-cycle, population-health and administrative services) through a local management services organization, and in states where corporate ownership of medical practice is restricted the Medical Group is a Non-Owned or Friendly entity that Privia manages but does not own. As of June 30, 2026 that network covered ~5,644 implemented providers, ~1,300 practices, ~6.1 million patients and ~1,647,000 attributed lives in value-based arrangements. Revenue arrives in three shapes: fee-for-service patient care (~$803.8 million in the first half of 2026, about ~65% of the total) plus administrative fees from Non-Owned groups, value-based revenue split across capitation (~$181.3 million), shared savings (~$143.9 million) and per-member-per-month care management fees (~$38.6 million), and a small amount of other services. Of every dollar of revenue, roughly ~79% goes straight back out as provider expense to the physicians who earned it.
ASTH vs PRVA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ASTH drivers: The shift toward full-risk contracts; Membership growth through acquisition and network additions.
- PRVA drivers: Provider adds and new-market entry drive the top line; The mix is shifting toward value-based care, which carries more margin and more risk.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The core risk is structural: with operating margin of ~2.6%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. For PRVA, payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle.
ASTH or PRVA: which should you pick?
If the story you believe is ASTH's (The shift toward full-risk contracts), ASTH is the more direct way to own it; if it is PRVA's (Provider adds and new-market entry drive the top line), PRVA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASTH and PRVA guides.
ASTH vs PRVA: the full fundamentals
ASTH. The gap between a ~27x trailing multiple and a ~8.5x forward multiple is the whole debate in one number: analysts expect EPS of ~$2.94 for 2026 and ~$3.48 for 2027, against ~$1.08 of trailing GAAP EPS, so the price depends on adjusted EBITDA converting into GAAP earnings. Market cap of ~$1.47 billion is well under half of trailing revenue (P/S ~0.37), which is normal for capitated healthcare because the company books the full premium dollar as revenue while keeping a thin slice. The nine analysts covering the stock have a mean target of ~$51.89, far above the November 20 price, which shows how far sentiment fell after the Q3 report.
PRVA. Operating figures are approximate and drawn from the Q3 2026 report, the Q2 2026 Form 10-Q and Yahoo Finance data, with market pricing as of November 20, 2026, so verify live data before acting on any of them. PRVA screens at ~1.3x sales and ~97x earnings at once because the sales figure includes the ~79% of revenue paid straight to physicians while the earnings figure is after tens of millions of annual stock compensation, so neither multiple describes the business on its own. The cleanest single comparison is enterprise value against adjusted EBITDA, roughly ~18x the guided 2026 midpoint, held next to double-digit revenue growth, ~19% attributed-lives growth and a debt-free balance sheet.
Headline figures (approximate, November 2026): ASTH shows market cap ~$1.47B (share price ~$29.53 on Nov 20, 2026), revenue (ttm) ~$3.91B, latest quarter up ~7% year over year, margins Gross ~11%, operating ~2.6%, net ~1.4%, net income (ttm) ~$53.1M, EPS ~$1.08; PRVA shows revenue (ttm) ~$2.43 billion GAAP revenue for the twelve months to September 30, 2026; Q3 2026 revenue ~$657.0 million, up ~13.2% and ahead of the ~$611 million consensus. 2026 guidance raised again on November 5 to a ~$2.53 billion revenue midpoint, practice collections vs revenue Practice Collections of ~$3.69 billion flowed through the platform in the twelve months to June 30, 2026, against ~$2.36 billion of GAAP revenue over the same period; the difference is collections at Non-Owned Medical Groups that Privia manages but does not consolidate, adjusted ebitda Q3 2026 ~$40.6 million versus a ~$39.0 million estimate; 2026 guidance midpoint ~$155.5 million; year to date ~28.8% of Care Margin, earnings, gaap versus yahoo-tracked eps Trailing GAAP net income ~$34.8 million (~$0.26 per share), profit margin ~1.4%; Q3 2026 net income ~$13.5 million. Q3 EPS on Yahoo's basis ~$0.21 versus a ~$0.23 estimate; stock compensation is the main gap to adjusted earnings.
The bottom line: ASTH vs PRVA
ASTH and PRVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ASTH and PRVA exposure against your real portfolio. It is not an investment adviser.
Wondering how ASTH or PRVA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Astrana Health
Ask Walnut's AI anything about ASTH and see how it fits what you own.
FAQ
What is the difference between ASTH and PRVA?
+
Astrana Health trades on Nasdaq under ASTH and was known as Apollo Medical Holdings (AMEH) until the 2024 rebrand. Privia Health Group is a national physician-enablement company headquartered in Arlington, Virginia, and its structure is unusual enough that it drives everything about the financials. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ASTH or PRVA the better stock?
+
Neither is universally better. PRVA is the larger incumbent; ASTH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ASTH or PRVA?
+
On forward P/E (as of November 2026), ASTH trades at 8.49x and PRVA at 23.25x, so ASTH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ASTH and PRVA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ASTH vs PRVA?
+
ASTH: The core risk is structural: with operating margin of ~2.6%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Leverage compounds this, with total debt of ~$977 million against ~$396 million of cash after the Prospect transaction, so integration missteps land on a balance sheet with less slack than before. Concentration is real on two axes, geography (California remains the dominant market) and counterparty (a small number of health plans account for a large share of revenue, and contract renegotiation or non-renewal would be material). Regulatory exposure runs in several directions at once: CMS rate notices and the v28 risk-adjustment phase-in set the revenue baseline, federal scrutiny of Medicare Advantage risk-adjustment coding continues industry-wide, and California legislation targeting management-services organizations and the corporate practice of medicine could reach Astrana's structure directly. Separately, an employment class action alleging meal and rest period violations (Case No. 26STCV21467, Los Angeles County Superior Court) is pending against Astrana Health Management; it is a wage-and-hour matter rather than a securities case, and no filed securities-fraud class action was identified as of the last refresh. The share price adds its own risk: a ~$18 to ~$52 52-week range shows how sharply sentiment swings on each cost-trend data point, and the ~21% slide in the month after the Q3 2026 EPS miss and below-consensus Q4 revenue guidance shows how quickly the market reprices when growth slows. PRVA: Payer concentration is the sharpest exposure: three payers accounted for ~27%, ~18% and ~17% of first-half revenue, and a single payer represented ~55% of net receivables at June 30, 2026, so one contract renegotiation or slow settlement moves both the income statement and the cash cycle. Cash flow itself is lumpy in a way the annual figure hides, because operating activities used ~$48.4 million in the first half of 2026 (versus ~$16.1 million used in the prior-year half) as accounts receivable built by ~$172.4 million ahead of shared-savings settlements, even though full-year 2025 operating cash flow was positive at ~$163.4 million. On March 24, 2026, after making a voluntary disclosure, Privia received a Request for Information or Assistance from the Department of Health and Human Services Office of Inspector General regarding a single former obstetric and gynecological Affiliated Practice in the Mid-Atlantic and whether it procured and implanted medical devices without complying with applicable requirements; the company is cooperating with OIG, the Department of Justice and the Virginia Attorney General, says it is unaware of similar conduct elsewhere, and does not currently expect a material adverse effect, but the scope is not yet determined. Structurally, most of the economics belong to the doctors (provider expense is ~79% of revenue), the physicians are independent and can leave, and the terms of Medicare Shared Savings, capitated and commercial value-based programs are set by CMS and payers rather than by Privia, so a rule change can reprice the fastest-growing revenue line. Finally, the valuation carries no cushion on reported earnings at roughly ~97x trailing GAAP net income as of November 20, 2026, and closing the gap to the ~$1.04 of trailing adjusted EPS requires accepting ~$71.1 million of annualized stock compensation as a non-expense while the share count keeps rising. Two smaller near-term watch items: EPS on the basis Yahoo tracks missed consensus in Q1, Q2 and Q3 2026 (~$0.19 versus ~$0.25, ~$0.19 versus ~$0.24 and ~$0.21 versus ~$0.23), so the raised guidance has yet to convert into per-share beats, and a Barron's roundup on September 18, 2026 listed Privia among companies with new activist filings at the SEC, without detail on who filed or what they seek.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ASTH or PRVA; figures are approximate and dated (as of November 2026). Verify current data before investing.